Sanchez-Vanegas G, et al. - In patients treated by primary care physicians in Colombia, researchers established the clinical effect and safety of betahistine (48 mg daily) for the management of peripheral vestibular vertigo. The study sample consisted of patients older than 15 years with a clinical diagnosis of peripheral vestibular vertigo who were candidates to be treated with betahistine (48 mg daily). According to this observational prospective cohort study, betahistine (48 mg daily) has a positive effect in controlling the symptoms of benign paroxysmal vertigo with an appropriate safety profile. No serious adverse events were recorded during the cohort follow-up and in no case was documented the suspension of treatment due to an adverse event.